$44.11
+0.07 (+0.16%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where EWTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
16 interventional · 1 with posted results
Held by 13 tracked-famous managers (Qube Research & Technologies Ltd, Artisan Partners Limited Partnership, CITADEL ADVISORS LLC, Schonfeld Strategic Advisors LLC, D. E. Shaw & Co., Inc., +8 more) · FINRA short interest 12.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Open-Label Extension of EDG-5506 in Participants With Becker Muscular DystrophyNCT06066580Number of adverse events in those treated with sevasemtenOpen-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Sevasemten | Becker Muscular Dystrophy | 260 | Feb 2031 | ≤ 1,654 d | 2026-07-31 |
| A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)NCT06347159Incidence of treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: EDG-7500, EDG-7500 | Hypertrophic Cardiomyopathy | 79 | Dec 2027 | ≤ 499 d | 2026-07-31 |
| Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyNCT06100887Number of adverse events during treatment with sevasemten or placeboRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Placebo | Duchenne Muscular Dystrophy | 43 | Mar 2027 | ≤ 224 d | 2025-11-06 |
| A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)NCT05540860Number of adverse events during treatment with sevasemten or placeboRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo | Duchenne Muscular Dystrophy | 76 | Jan 2027 | ≤ 165 d | 2025-11-12 |
| Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)NCT05291091Number of adverse events in those treated with sevasemten or placeboRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo | Becker Muscular Dystrophy | 244 | Sep 2026 | ≤ 42 d | 2026-07-31 |
| A Study to Evaluate EDG-7500 in Caucasian and Japanese AdultsNCT07456059AUC0-lastOpen-label · Basic science | Phase 1 | Completed | Drug: EDG-7500 | Healthy Adult Participants | 24 | 2026-06-01actual | — | 2026-07-31 |
| A Study of EDG-15400 in Healthy AdultsNCT07177066Safety: incidence of treatment-emergent adverse eventsRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: EDG-15400, Placebo | Healthy Adults | 84 | 2026-04-29actual | — | 2026-08-05 |
| A Study to Evaluate EDG-7500 in Adults With Hepatic ImpairmentNCT07324616Area under the plasma concentration time-curve from time zero to the last measured concentration (AUC0-last)Open-label · Treatment | Phase 1 | Completed | Drug: EDG-7500 | Hepatic Impairment (HI) | 25 | 2026-04-07actual | — | 2026-07-31 |
| A Study to Evaluate EDG-7500 in People With Renal ImpairmentNCT07034768Area under the curve from time zero to last quantifiable concentration (AUC0-last)Open-label · Basic science | Phase 1 | Completed | Drug: EDG-7500 | Renal Impairments | 37 | 2025-12-22actual | — | 2026-03-12 |
| A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy VolunteersNCT06916897PharmacokineticRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: sevasemten, Verapamil | Healthy Subjects | 42 | 2025-02-22actual | — | 2025-04-08 |
| A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500NCT06738836Mass BalanceOpen-label · Treatment | Phase 1 | Completed | Drug: [14C]-EDG-7500 | Healthy Volunteer | 8 | 2025-01-17actual | — | 2025-04-16 |
| A Study of EDG-7500 in Healthy AdultsNCT06011317Safety: incidence of treatment-emergent adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: EDG-7500, Placebo | Healthy Subjects | 84 | 2024-05-23actual | — | 2024-07-16 |
| A Study of EDG-5506 in Adult Males With Becker Muscular DystrophyNCT05160415results2025-06-24Percentage of Participants Treated With Sevasemten Experiencing AEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Sevasemten | Becker Muscular Dystrophy | 12 | 2024-03-01actual | — | 2025-06-24 |
| Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy VolunteersNCT05730842The mass balance of EDG-5506 as measured by the total radioactivity recovered in urineNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous | Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn | 15 | 2023-04-06actual | — | 2023-04-18 |
| A Study to Assess the Feasibility of Non-invasive Dried Blood SamplingNCT05492734Difference in area under the concentration-time curve (AUC0-24, AUC0-26, AUC0-144 and AUC0-t) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood samplingOpen-label · Treatment | Phase 1 | Completed | Drug: EDG-5506 | Muscular Dystrophies | 10 | 2022-08-19actual | — | 2022-09-02 |
| A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy AdultsNCT04585464Incidence, frequency, severity and dose-relationship of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: EDG-5506, Placebo | Healthy Volunteer, Becker Muscular Dystrophy | 127 | 2021-11-15actual | — | 2022-06-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19